Principal Technologies Inc. Stock OTC Markets

PTEKF

CA74260Q1028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

06-26	Principal Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-02	Principal Technologies Inc. announced that it expects to receive CAD 1.1015 million in funding	CI

Valuation: Principal Technologies Inc.

Market Cap	20.5M 14.45M 12.63M 11.59M 10.81M 1.38B 20.84M 140M 54.1M 675M 54.25M 53.08M 2.32B	P/E 2024 *	-	P/E 2025	-2x
Enterprise Value	19.49M 13.74M 12.01M 11.03M 10.28M 1.31B 19.82M 133M 51.45M 642M 51.6M 50.48M 2.21B	EV / Sales 2024	7,172,726x	EV / Sales 2025	25,290,400x
Free-Float	64.65%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Principal Technologies Inc.

06-26	Principal Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-02	Principal Technologies Inc. announced that it expects to receive CAD 1.1015 million in funding	CI
03-27	Principal Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2026	CI
12-30	Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2025	CI
12-15	Principal Technologies closes private placement financing	RE
12-14	Principal Technologies Inc. announced that it has received CAD 1.2 million in funding	CI
11-29	Principal Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2025	CI
11-28	Principal Technologies Inc. Auditor Raises 'Going Concern' Doubt	CI
11-28	Principal Technologies Announces Private Placement Financing	MT
11-26	Principal Technologies Inc. announced that it expects to receive CAD 1.2 million in funding	CI
25-10-31	The management of E&E Cro Consulting GmbH agreed to acquire 60% stake in E&E Cro Consulting GmbH from Principal Technologies Inc. in a management buyout transaction.	CI
25-10-31	Principal Technologies Partners With University of Oxford on Thermal Sensor for Cancer Applications	MT
25-10-31	Principal Technologies Inc. Enters into Research and Development Agreement with the University of Oxford	CI

More news

Press Releases: Principal Technologies Inc.

06-03	PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING AND DEBT SETTLEMENT TRANSACTIONS	AQ
12-15	PRINCIPAL TECHNOLOGIES CLOSES PRIVATE PLACEMENT FINANCING	AQ
11-27	PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING	AQ
25-10-31	PRINCIPAL TECHNOLOGIES ENTERS R&D AGREEMENT WITH OXFORD AND DIVESTS OF MAJORITY OWNERSHIP OF E&E CRO CONSULTING	AQ
25-07-28	PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING	AQ

More press releases

Managers and Directors: Principal Technologies Inc.

Manager	Title	Age	Since
Gerald Trent CEO	Chief Executive Officer	47	2021-08-03
Peter McKeown DFI	Director of Finance/CFO	70	2023-03-05

Director	Title	Age	Since
Leopold Specht BRD	Director/Board Member	70	2021-08-03
Alfred von Liechtenstein CHM	Chairman	55	-
Gerald Trent BRD	Director/Board Member	47	2021-08-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PRINCIPAL TECHNOLOGIES INC.	-.--%	-.--%	-	-	14.45M
LONZA GROUP AG	-0.05%	+5.65%	+1.44%	+6.69%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+6.21%	+408.85%	+607.44%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+11.06%	+25.75%	-7.89%	34.55B
BEONE MEDICINES AG	+2.38%	+8.10%	+21.83%	+66.94%	33.09B
CELLTRION, INC.	+1.20%	+2.02%	+9.79%	+32.43%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+4.94%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+7.24%	+71.03%	+132.17%	15.92B
EUROFINS SCIENTIFIC SE	-0.06%	+0.23%	+13.27%	+18.68%	13.83B
ICON PUBLIC LIMITED COMPANY	-1.14%	+7.52%	+14.75%	-30.83%	13.26B
Average	+1.03%	+6.43%	+70.84%	+103.20%	26.92B
Weighted average by Cap.	+1.15%	+6.73%	+88.30%	+130.90%

See all sector performances

Principal Technologies Inc. is a Canada-based healthcare acquisition company. The Company is engaged in building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential which have intellectual property capable of enhancing medical treatment quality, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. The Company operates through the health-care technology segment, including the project management of international scale clinical studies primarily related to medical device technologies. Its subsidiaries include Principal Technologies Capital Management GmbH and E&E CRO Consulting GmbH.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

As early as today, start finding the best investment opportunities!

3 years	0		0.27
5 years	0		0.27
10 years	0		0.27

	2024	2025
Net sales	0.66 0.47 0.41 0.38 0.35 44.56 0.68 4.52 1.75 21.86 1.76 1.72 75.32	0.37 0.26 0.23 0.21 0.2 24.86 0.38 2.52 0.98 12.19 0.98 0.96 42.01
Net income	-1.62M -1.14M -995K -914K -852K -108M -1.64M -11M -4.26M -53.16M -4.27M -4.18M -183M	-4.24M -2.99M -2.61M -2.4M -2.23M -284M -4.31M -28.84M -11.18M -139M -11.21M -10.97M -480M
Net Debt	-767K -541K -473K -434K -405K -51.5M -780K -5.23M -2.03M -25.26M -2.03M -1.99M -87.04M	-1M -707K -618K -567K -529K -67.31M -1.02M -6.83M -2.65M -33.02M -2.65M -2.6M -114M

Principal Technologies Inc. Stock OTC Markets

Stocks

PTEKF

CA74260Q1028

Biotechnology & Medical Research

Valuation: Principal Technologies Inc.

Latest news : Principal Technologies Inc.

Press Releases: Principal Technologies Inc.

Course Extremes

Managers and Directors: Principal Technologies Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates